ResearcherKyushu UniversityActive in the last 2 years
Ryuichiro Kimura
Matched on ORCID iD 0000-0001-5278-7827; OpenAlex author ID A5038313055. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 4
- Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17792↗
- FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Co-author DOI 10.1007/s00595-020-02123-2↗
- Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced-stage cancer? Co-author DOI 10.1002/ags3.12340↗
- Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. Co-author DOI 10.1245/s10434-019-07309-8↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yasuhisa Mori · 4 shared papers, 2019–2025 · strength 0.55
- Paper Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. DOI 10.21873/anticanres.17792↗
- Paper FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experienc… DOI 10.1007/s00595-020-02123-2↗
- Paper Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced… DOI 10.1002/ags3.12340↗
- Kohei Nakata · 4 shared papers, 2019–2025 · strength 0.55
- Paper Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. DOI 10.21873/anticanres.17792↗
- Paper FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experienc… DOI 10.1007/s00595-020-02123-2↗
- Paper Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced… DOI 10.1002/ags3.12340↗
- Takao Ohtsuka · 4 shared papers, 2019–2025 · strength 0.55
- Paper Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. DOI 10.21873/anticanres.17792↗
- Paper FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experienc… DOI 10.1007/s00595-020-02123-2↗
- Paper Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced… DOI 10.1002/ags3.12340↗
- Masafumi Nakamura · 3 shared papers, 2020–2025 · strength 0.46
- Paper Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. DOI 10.21873/anticanres.17792↗
- Paper FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experienc… DOI 10.1007/s00595-020-02123-2↗
- Paper Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced… DOI 10.1002/ags3.12340↗
- Yoshinao Oda · 3 shared papers, 2019–2025 · strength 0.43
- Paper Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. DOI 10.21873/anticanres.17792↗
- Paper Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced… DOI 10.1002/ags3.12340↗
- Paper Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially I… DOI 10.1245/s10434-019-07309-8↗
- Yoshihiro Miyasaka · 3 shared papers, 2019–2025 · strength 0.43
- Paper Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. DOI 10.21873/anticanres.17792↗
- Paper Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced… DOI 10.1002/ags3.12340↗
- Paper Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially I… DOI 10.1245/s10434-019-07309-8↗
- Noboru Ideno · 1 shared paper, 2025 · strength 0.22
- Takashi Taniguchi · 1 shared paper, 2025 · strength 0.22
- Ryota Matsuda · 2 shared papers, 2019–2020 · strength 0.20
- Paper Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced… DOI 10.1002/ags3.12340↗
- Paper Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially I… DOI 10.1245/s10434-019-07309-8↗
- Yusuke Watanabe · 1 shared paper, 2021 · strength 0.12
- Atsushi Fujii · 1 shared paper, 2021 · strength 0.12
- Kenoki Ohuchida · 1 shared paper, 2021 · strength 0.12
- Naoki Ikenaga · 1 shared paper, 2021 · strength 0.12
- Koji Shindo · 1 shared paper, 2021 · strength 0.12
- Masato Watanabe · 1 shared paper, 2020 · strength 0.11
- Masafumi Nakamura · 1 shared paper, 2019 · strength 0.09
- Nao Fujimori · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.